New hope for tough prostate cancer: trial tests Two-Pronged attack
NCT ID NCT06836726
Summary
This study is testing whether adding a new drug called evofosfamide to standard hormone therapy can help control advanced prostate cancer that has stopped responding to initial treatments. It will involve about 35 men whose cancer has spread and progressed despite prior therapy. Researchers will use advanced scans and blood tests to see if the combination slows cancer growth and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Center
Toronto, Ontario, M7A 2S4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.